【ChiCTR2000033777】Effects of a live streaming Mindfulness Yoga - Practice Awareness through Cognitive-based Exercise (MY-PACE) Program on balance and gait for People with Parkinson’s Disease: A Randomised Controlled Trial
ChiCTR2000033777
尚未开始
/
/
/
2020-06-12
/
/
Parkinson's disease
Effects of a live streaming Mindfulness Yoga - Practice Awareness through Cognitive-based Exercise (MY-PACE) Program on balance and gait for People with Parkinson’s Disease: A Randomised Controlled Trial
Effects of a live streaming Mindfulness Yoga - Practice Awareness through Cognitive-based Exercise (MY-PACE) Program on balance and gait for People with Parkinson’s Disease: A Randomised Controlled Trial
To examine the comparative effects between Mindfulness Yoga – Practice Awareness through Cognitive-based Exercise (MY-PACE) and usual care service only for Chinese patients with mild-to-moderate PD, on the following physio-psycho-cognitive outcomes: a)functional mobility (primary outcome), b)perceived balance confidence (primary outcome), c)gait, d)PD-related motor symptoms, e)anxiety and depressive symptoms, f)mindfulness, g)cognitive function, and, h)HRQOL.
随机平行对照
其它
Eligible participants will be randomly assigned into one of the following conditions on 1:1 basis using a randomization table produced using computer-assisted random number generator.
Single-blinded
University Fund
/
56
/
2020-06-22
2022-09-30
/
To be eligible for inclusion, individuals must be (1) diagnosed with idiopathic PD (Hoehn and Yahr stage I-III); (2) aged >=18 years; (3) able to walk with or without an assistive device; (4) able to give written consent, and (5) have access to smartphone/ tablet device and Internet connection.；
请登录查看Individuals will be excluded if they: (1) are currently participating in any other behavioural or pharmacological trial; (2) have significant cognitive impairment as indicated by the Hong Kong Montreal Cognitive Assessment 5-min protocol (HK-MoCA), cutoff scores based on the age and education corrected normative data will be used [11] [12], or (3) have serious medical conditions except PD, or other contraindication to mild-to-moderate physical exertion that might limit their full participation (e.g. severe hearing or vision impairment, significant orthopaedic problems, etc.).；
请登录查看香港大學李嘉誠醫學院護理學院
/
香港大學李嘉誠醫學院護理學院的其他临床试验
香港大學李嘉誠醫學院護理學院的其他临床试验
最新临床资讯
-
大鹏制药临床III期成功
新药说2026-08-13
-
新一代 EGFR-TKI 首个全球 III 期成功
丁香园 Insight 数据库2026-08-13
-
体外诊断原料网2026-08-13
-
佰傲谷BioValley2026-08-13
-
久有基金2026-08-13
-
重庆宸安生物2026-08-13
-
UmabsDB2026-08-13
-
希格生科2026-08-13
-
bioSeedin柏思荟2026-08-13
-
智飞智讯2026-08-13
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-08-13
-
2026-08-13
-
2026-08-13
-
摩熵咨询 20 8
-
摩熵咨询 34 28
-
摩熵咨询 20 5
-
颁布机构：四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
-
颁布机构：国家医保局 2026-07-31
-
颁布机构：国家药品审评中心（CDE） 2026-07-24
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-08-13
-
2026-08-13
-
2026-08-13
-
摩熵咨询 35 36
-
摩熵咨询 28 39
-
摩熵咨询 34 18
-
颁布机构：国家市场监督管理总局 2026-08-10
-
颁布机构：国家市场监督管理总局 2026-05-29
-
颁布机构：国家市场监督管理总局 2026-05-29